Tatva Chintan Pharma Chem Ltd.
Yagnesh Patel 
Detail Stock analysis report on Tatva Chintan Pharma Chem. Ltd with specific levels of Support & resistance
Tatva Chintan Pharma Chem Ltd
- The stock witnessed a sharp downside rally starting in September 2024. The stock declined from its high of ₹1102 to a low of ₹788 in October 2024, marking an approximate 28% correction within just one and a half months.
- Following this significant price correction, the stock entered a consolidation phase in October 2024. It consistently held the ₹800 level, testing it multiple times. This repeated testing of the support level indicates a strong base formation around this price point.
- The stock has comfortably broken above its mid-term 55 SMA, a key indicator of a potential trend change. Additionally, the stock closed above its short-term 20 SMA, providing further confirmation of a likely trend reversal.
- A falling trend line breakout occurred on the last trading day, confirming the reversal of the prior downtrend. The breakout was accompanied by rising volumes, adding further credibility to this trend reversal.
- The Weekly RSI shows a positive divergence, indicating that the momentum is improving even as prices were previously declining, strengthening the case for a bullish reversal.
Conclusion: We are expecting stock price may go up side from here cmp – 895 levels
Important Resistance: 898 - 955 - 997
Important Support: 875 - 856 - 815
Analyst: Yagnesh Patel
Telegram Channel: Click Here
SEBI Registered Research Analyst
Registration Number: INH000016320
Email: support@yagneshpatel.in
Disclaimer-
I’m SEBI Registered RA. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.
SEBI registered RA number INH000016320.
Categories: : Stocks For Watchlist